Comparing the current results to its competitors, Inspire Medical Systems Inc reported Revenue increase in the 1 quarter 2026 by 1.65 % year on year. The revenue growth was below Inspire Medical Systems Inc 's competitors' average revenue growth of 8.3 %, achieved in the same quarter.
Inspire Medical Systems inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 43.64 %
Inspire Medical Systems Inc 's Comment on Competition and Industry Peers
The company offers the FDA-approved Inspire therapy, a closed-loop, minimally invasive neurostimulation treatment for moderate to severe obstructive sleep apnea (OSA) patients who fail or cannot tolerate positive airway pressure (PAP) treatments such as CPAP. Competitors in the PAP market include ResMed Inc., Philips BV, Fisher & Paykel Healthcare Corporation Limited, and various regional and new-entrant manufacturers. In the US, the only direct neurostimulation competitor is Nyxoah SA and its subsidiary Nyxoah, Inc., which provide an open-loop, bilateral stimulation system without a respiratory sensor. LivaNova PLC has submitted an FDA application for a hypoglossal nerve stimulation device in the US. Outside the US, Nyxoah and LivaNova market similar second-line therapies. Additionally, Apnimed is developing a pharmaceutical treatment for OSA currently in Phase 3 trials, and the GLP-1 drug Zepbound (tirzepatide) received FDA approval in December 2024 for OSA treatment.
November 12, 2025
Stride, Inc. Under Legal Scrutiny Amidst Competitive Market Pressures: A Comprehensive Analysis of Its Financial Standing In a landscape increasingly marked by shareholder activism and scrutiny, Stride, Inc. (NYSE: INSP) has found itself facing a significant class action lawsuit, raising pivotal questions about its governance and operational performance. Announced on November 12, 2025, by the law firm Gainey McKenna and Egleston, the suit, filed in the United States District Court for the Eastern District of Virginia, centers on allegations against Stride related to its securities and market performance during a critical window. The implications of this legal action arrive amidst contrasting financial result...
July 19, 2024
Inspire Medical Systems Achieves Full-Body MRI Compatibility Approval under EU MDR, Revolutionizing Treatment for Sleep Apnea PatientsMINNEAPOLIS, July 19, 2024 - Inspire Medical Systems, Inc. (NYSE: INSP), a leading medical technology company specializing in innovative, minimally invasive solutions for obstructive sleep apnea (OSA) patients, has recently announced a significant breakthrough in the treatment of this disorder. The European Union Medical Device Regulation (EU MDR) has granted Inspire full-body magnetic resonance imaging (MRI) compatibility for their Inspire therapy. This marks a pivotal moment in the company s history, as it expands the previously limited MRI scan conditions to include the ent...
Inspiremd Inc is a medical device company that develops and commercializes stent systems for the treatment of coronary artery disease. Their business model revolves around the production and distribution of their proprietary stent systems to healthcare providers worldwide.
Neuropace Inc's business model revolves around the development and commercialization of medical devices for the treatment of neurological disorders, primarily focusing on epilepsy.
Meihua International Medical Technologies Co Ltd Share Performance
-85.00%
One Year
Meihua International Medical Technologies Co Ltd
Profile
Meihua International Medical Technologies Co. Limi operates on a business model focused on the development and distribution of medical technologies and solutions. The company aims to deliver innovative and quality medical equipment to healthcare providers and institutions globally. By leveraging their expertise and partnerships, Meihua strives to enhance healthcare outcomes and contribute to the advancement of medical technology.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Inspire Medical Systems inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inspire Medical Systems inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
